Newsroom

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of SoundThinking, Inc. (NASDAQ: SSTI) to Transom Capital Group for $8.00 per share in cash, and one non-transferable contingent value right worth up to $3.00 per share. Halper Sadeh encourages SoundThinking shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersad...

WILMINGTON, Del.--(BUSINESS WIRE)--Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of overall survival (OS) and in the key secondary endpoint of progression-free survival (PFS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Harte Hanks, Inc. (NASDAQ: HHS) to Star Equity Holdings, Inc. Under the terms of the proposed transaction, Harte Hanks shareholders may elect to receive either (1) $5.00 in cash for each Harte Hanks share, or (2) 0.50 shares of Star Equity’s publicly traded 10% Series A Cumulative Perpetual Preferred Stock for each Harte Hanks share.Halper Sadeh encourages Harte Hanks shareholders to click here...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of GoPro, Inc. (NASDAQ: GPRO) to Starman Optical, Inc. for $1.14 per share, subject to potential adjustment based on GoPro’s net working capital at closing. Halper Sadeh encourages GoPro shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investig...

CAMARILLO, Calif.--(BUSINESS WIRE)--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, is adding new resilient communications building blocks to its AirLink® 5G Networking Solutions. Semtech will demonstrate the new capabilities in booth #2964 at the International Association of Chiefs of Police (IACP) conference in Orlando, Fla. First responders rel...

WHIPPANY, N.J.--(BUSINESS WIRE)--ESMO 2026: NUBEQA® plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...

COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi...

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer...